Microvascular Angina in Men: When a Negative Stress Test Is Not the Same as a Clear Bill of Health

A man in his late 40s sees a cardiologist for exertional chest pressure. He has been getting it for six months, reliably, on the third flight of stairs, or the third block at a faster pace. It resolves at rest within five minutes. He describes it as a heaviness, sometimes moving to the jaw. He is a former smoker. His blood pressure runs 138/86. His fasting glucose is 104 mg/dL. His stress test is normal. He is told his heart is fine.

Six months later he returns with the same complaint.

His stress test was designed to detect obstructive coronary artery disease, a blockage of 70 percent or more in a large artery. It was not designed to detect coronary microvascular dysfunction, and it will not reliably identify it. If the ischemia in his small coronary vessels is the mechanism behind his exertional chest pain, the standard diagnostic pathway will not find it, and he will be reassured with increasing frequency while the underlying mechanism continues unaddressed.

What the Coronary Microvasculature Does

The coronary arterial tree is not one uniform system. The large epicardial coronary arteries, the vessels that standard angiography visualizes and that stents are placed in, are the distribution vessels. They carry blood from the aorta into the heart muscle. They are typically larger than 500 micrometers in diameter.

The microvasculature, arterioles from 10 to 500 micrometers, capillaries below 10 micrometers, is the delivery system. These vessels are where the actual gas exchange happens: where oxygen crosses into heart muscle cells and waste products cross back into blood. At rest, the microvasculature maintains adequate flow. During exercise, metabolic demand increases, and the microvasculature must dilate to increase coronary blood flow appropriately, sometimes threefold to fivefold over resting levels.

The ability of the microvasculature to dilate in response to increased demand is measured by the coronary flow reserve (CFR): the ratio of maximum hyperemic flow to resting flow. A normal CFR is above 2.5 to 3.0. When CFR falls below 2.0, the microvasculature cannot adequately increase flow to meet demand. The result is ischemia, not from a large artery blockage, but from the inability of the small vessels to deliver enough blood to the contracting myocardium.

Standard coronary angiography images vessels above approximately 500 micrometers. The microvasculature is physically invisible on angiography. A man with profound microvascular dysfunction and a CFR of 1.2, severely impaired flow reserve, can have an angiogram that looks completely normal.

Why CMD in Men Gets Missed

The clinical narrative around coronary microvascular dysfunction has evolved in two phases that created a diagnostic bias in men.

The first phase, in the 1980s and 1990s, recognized that women with anginal symptoms and clean angiograms were not simply having anxiety or non-cardiac pain, they had real myocardial ischemia from small-vessel disease. This was an important recognition, captured in studies like the WISE trial (Women’s Ischemia Syndrome Evaluation), which documented the prevalence and prognosis of CMD in women with non-obstructive coronary disease.

The second phase was the clinical translation of that research, which occurred substantially within a women’s health framework. CMD entered clinical training primarily through the lens of women’s cardiovascular disparities, a real and important lens, but one with a side effect: it implicitly labeled CMD as a women’s disease. Men with chest pain and clean angiograms were less likely to be evaluated for CMD because the condition was not in the differential when the default patient was male.

The result is a documented bias in CMD evaluation. Studies comparing CMD workup rates between sexes in patients with non-obstructive coronary disease show that men are less likely to receive invasive coronary function testing, less likely to have CFR measured, and less likely to have the diagnosis of CMD applied when present.

The Metabolic Connection in Men

Coronary microvascular dysfunction in men is often metabolically mediated, and this is the key difference in mechanism from the dominant CMD presentation in women.

In women, CMD frequently occurs through autoimmune-related endothelial injury, hormonal changes (particularly the endothelial dysfunction associated with estrogen decline at menopause), and autonomic dysregulation. These are the mechanisms emphasized in the women’s CMD literature.

In men, particularly in the 40 to 60 age range, CMD more commonly occurs in the context of insulin resistance, metabolic syndrome, hypertension, and a smoking history. The mechanism runs through impaired nitric oxide production: insulin resistance reduces endothelial nitric oxide synthase (eNOS) activity, diminishing the primary endothelium-derived vasodilator signal. Without adequate nitric oxide, the microvascular arterioles cannot dilate appropriately in response to metabolic demand. The result is supply-demand mismatch during exercise, ischemia from inability to vasodilate, not from anatomic obstruction.

Elevated endothelin-1, the primary endothelial vasoconstrictor, is measurably elevated in men with metabolic syndrome and inversely correlates with coronary flow reserve in cardiac PET studies. Chronic low-grade inflammation, elevated hsCRP, elevated IL-6, elevated TNF-alpha, damages microvascular integrity and contributes to CMD.

The practical implication: a man with metabolic syndrome who develops exertional chest pain and a clean angiogram should have the metabolic drivers of CMD on the differential, not just be reassured that “it’s not cardiac.”

How to Test for CMD in Men

The diagnostic pathway for CMD in men begins with clinical recognition, understanding that exertional chest pain with a normal stress test and clean angiogram in a man with metabolic risk factors is not conclusively non-cardiac.

Step 1: Reassess the stress test. A standard exercise ECG is insensitive for CMD. It detects ischemia that is large enough to produce ECG changes at peak exercise, typically from macrovascular disease. A nuclear stress test (SPECT imaging) is more sensitive but still uses semi-quantitative perfusion analysis that may miss the diffuse, mild-to-moderate hypoperfusion pattern of CMD. Cardiac PET with absolute myocardial blood flow quantification measures CFR non-invasively and is the most sensitive non-invasive tool for CMD.

Step 2: Consider cardiac MRI. Cardiac MRI with stress perfusion imaging (using adenosine or regadenoson) provides visualization of regional and subendocardial perfusion defects that SPECT misses. The subendocardium is the most vulnerable region in CMD because it has the highest oxygen demand and is most dependent on microvascular reserve. Cardiac MRI can detect the subendocardial perfusion impairment pattern characteristic of CMD.

Step 3: Invasive coronary function testing if non-invasive testing is inconclusive and symptoms persist. This is performed during cardiac catheterization with a pressure-temperature wire. Coronary flow reserve is measured with adenosine hyperemia; the index of microcirculatory resistance (IMR) quantifies microvascular resistance directly. A CFR below 2.0 with elevated IMR confirms CMD. Acetylcholine provocation testing can additionally identify coronary vasospasm as a contributing or alternative mechanism.

Treatment: Targeting the Metabolic Root Cause

For men with metabolically mediated CMD, the most consequential interventions are often not cardiac medications, they are metabolic interventions that improve microvascular function from the root.

Treating insulin resistance is the highest-yield intervention for many men with metabolic CMD. Weight loss, even 5 to 10 percent of body weight, measurably improves coronary flow reserve in men with obesity-related CMD. Aerobic exercise training improves endothelial nitric oxide synthase activity and coronary flow reserve independent of weight loss. The CALERIE trial showed substantial improvements in endothelial function markers with moderate caloric restriction. Metformin improves vascular endothelial function in men with insulin resistance through AMPK-mediated eNOS activation and is sometimes used off-label in men with CMD and prediabetes for this reason.

Blood pressure control directly reduces the fixed microvascular resistance that impairs CFR. ACE inhibitors and angiotensin receptor blockers have endothelial-protective effects beyond blood pressure reduction, they reduce angiotensin II-mediated vasoconstriction and improve microvascular remodeling. In men with CMD and hypertension, ACE inhibitors or ARBs are the preferred antihypertensive class.

Statin therapy has anti-inflammatory and endothelial-protective effects relevant in CMD: statins reduce the endothelial inflammatory response and improve eNOS coupling. The pleiotropic effects of statins in CMD may be as important as their lipid-lowering action in men without severely elevated LDL.

For symptom management, the evidence base includes ranolazine (reduces late sodium current in ischemic myocardium, shown to reduce angina burden in CMD), beta-blockers (reduce myocardial oxygen demand, improving the supply-demand balance), and long-acting nitrates (for symptomatic relief of acute episodes). Calcium channel blockers, particularly diltiazem, are used when vasospasm is a component of the CMD presentation.

What “Your Angiogram Is Clean” Does Not Mean

This is the sentence that sends men home without answers: “your angiogram was normal.” It means the large epicardial coronary arteries have no obstructive plaque. It does not mean the heart is receiving adequate blood flow under stress. It does not mean the microvasculature is functioning. It does not mean exertional chest pain is benign.

The conceptual framework underlying that statement, that a clean angiogram is synonymous with a clean cardiac bill of health, was built at a time when coronary artery disease was understood almost exclusively through macrovascular blockages. The WISE study in 2006 challenged that framework for women. The literature on CMD in men has been slower to accumulate, but the physiology is not fundamentally different.

A man with exertional chest pain and a clean angiogram has been evaluated for one category of cardiac disease. He has not been evaluated for the microvascular category. These are not the same test.

Why the Standard Stress Test Misled You

Understanding why a normal stress test does not rule out CMD requires understanding what the standard stress test was designed to detect.

A treadmill exercise ECG test detects ischemia that produces ECG changes (typically ST segment depression) at peak exercise. For ECG changes to appear, a significant proportion of myocardial territory must become ischemic, typically from a lesion in a large coronary artery reducing flow to a large segment of muscle. This test was improved to detect obstructive macrovascular disease: a blockage of 70 percent or greater in a major coronary artery.

Nuclear stress testing (SPECT myocardial perfusion imaging) increases sensitivity by detecting regional differences in tracer uptake between rest and stress. It is substantially more sensitive than ECG stress testing for obstructive disease. However, SPECT imaging has fundamental limitations for CMD: the perfusion defects in CMD tend to be diffuse and subendocardial rather than focal and transmural. When perfusion is globally reduced rather than regionally reduced, standard SPECT semi-quantitative analysis frequently reads the study as normal, because there is no regional gradient against which to compare the abnormal areas.

Cardiac PET with absolute myocardial blood flow quantification overcomes this limitation by measuring actual blood flow in milliliters per gram per minute, not relative regional uptake. A man with globally impaired myocardial perfusion at stress shows a low absolute flow number even if regional distribution is symmetric. PET is the most sensitive non-invasive tool for CMD, but it is not universally available and is less frequently ordered in men with chest pain and clean angiograms because CMD is not on the differential.

The phrase “your stress test was normal” from your previous evaluation means your large-artery obstructive disease risk was assessed and found acceptable. It does not mean your microvascular function was assessed.

The Prognosis: CMD Is Not a Benign Condition

The WISE data on women established that CMD with a coronary flow reserve below 2.0 carries a 27.6 percent major adverse cardiovascular event rate over five years. Men-specific CMD outcome data are more limited, but available series show elevated event rates, 5- to 10-year MACE rates in men with CMD in the range of 20 to 30 percent in specialized referral populations.

This is not anxiety. This is not a “cardiac neurosis.” This is impaired myocardial perfusion with documented longitudinal cardiovascular risk. The man who is told his heart is fine because his angiogram is normal and then has a major cardiovascular event in the next five years is a man whose CMD was not identified.

Appropriate recognition, diagnostic evaluation, and metabolic-targeted treatment can reduce symptoms substantially and may improve the trajectory of microvascular function over time. The goal is not to reassure, it is to diagnose accurately and treat the mechanism.

What to Do This Week

If you have exertional chest pain that has been evaluated with a stress test and angiography and told “your heart is fine”, but the symptoms persist, the appropriate next question is not “why do I keep having chest pain if my heart is fine?” The appropriate question is: “Was my microvascular function evaluated?”

Ask your cardiologist whether coronary flow reserve was measured, either non-invasively (cardiac PET or MRI with perfusion) or invasively (coronary function testing with adenosine in the catheterization laboratory). Ask whether the functional reserve of your microvasculature was assessed, not just the anatomy of your large arteries.

If you have metabolic syndrome, elevated waist circumference, elevated triglycerides, low HDL, hypertension, or prediabetes, ask specifically whether CMD has been considered in the context of your cardiovascular risk profile. These are the men in whom the metabolic-microvascular connection is most clinically relevant.

The standard cardiac workup is designed for the most common and most dangerous presentation of heart disease. It is not designed to rule out all categories of heart disease. CMD in men is one of the categories it routinely misses. A man who continues to have exertional chest pain after a normal stress test and clean angiogram has not been fully evaluated, he has been evaluated for one mechanism and found clear on that one mechanism. The evaluation is incomplete, not the answer.

The Signal Check is fifteen questions mapping the male cardiovascular risk pattern, including the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.